Our mission is to enhance women’s lives by providing clinically proven, non-invasive products to improve female
Stress Urinary Incontinence

Learn More About Viveve

The Viveve PURSUIT Trial is a pivotal U.S. Stress Urinary Incontinence trial that has completed all subject 12-month follow-up visits

Topline results of primary efficacy endpoint planned in January 2023.

Read More

Viveve Reports Third Quarter 2022 Financial Results

Read The Report

Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Read The Announcement

Pivotal U.S. Investigational Device Exemption (IDE) cleared trial

PURSUIT is a randomized, double-blinded, sham-controlled, IDE-cleared trial that enrolled 415 subjects with moderate SUI at approximately 30 study sites in the United States. Subjects were randomized in a 2:1 ratio to the active Viveve treatment or an inert sham treatment.

Viveve aspires to be the leader
in the treatment of female
Stress Urinary Incontinence

The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency (CMRF) technology to uniformly provide an endovaginal treatment that is non-ablative.

user-tie

The Viveve Leadership Team

The Viveve leadership team is an experienced group of individuals dedicated to upholding our values and achieving our vision and mission.

Meet the Senior Leadership Team

Interested in learning more about Viveve?

Learn More About Viveve

Product Indications

Viveve System
The Viveve System is indicated for general surgery for electrocoagulation and hemostasis in the United States.
Viveve Solutions
The Viveve System is indicated for general surgery for electrocoagulation and hemostasis in the United States. The InControl Products (InToneMV) is indicated for the treatment of all forms of urinary incontinence in the United States and Canada.